비교리스트

 카트 문의
시장보고서
상품코드
1440017

세계의 암 면역치료 시장 : 인사이트, 경쟁 구도 및 시장 예측(2030년)

Cancer Immunotherapy - Market Insights, Competitive Landscape, and Market Forecast - 2030
발행일: | 리서치사: DelveInsight | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

세계의 암 면역치료 시장 규모는 2022년에 852억 3,000만 달러로 평가되었고, 2030년까지 1,628억 7,000만 달러에 이를 전망이며, 2024년부터 2030년까지 예측기간에 CAGR 11.63%의 성장이 전망됩니다. 시장은 세계 암의 유병률 상승과 발암성 물질, 흡연, 방사선, 바이러스 등에 대한 노출 증가 등의 요인에 의해 낙관적인 시장 성장을 보여주고 있습니다. 게다가 의료 지출의 급증이나 기타 치료법보다 암 면역치료의 채용이 증가하고 있는 것도, 소정의 예측 기간에 있어서 시장을 견인합니다. 따라서 시장은 2024년부터 2030년까지 예측 기간에 대폭적인 CAGR의 성장이 추정됩니다.

암 면역치료 시장 역학

암 면역치료 시장을 견인하는 중요한 특징 중 하나는 세계의 암 유병률의 상승입니다.

예를 들어 세계보건기구(WHO)(2022)에 따르면 2020년 유방암 이환수는 226만 건, 이어 폐암 221만 건, 대장암 193만 건, 전립선암 141만 건, 피부암 120만 건, 위암 109만 건입니다. 또한 유럽위원회의 데이터베이스에 따르면 2020년 유럽에서 여성의 암 이환율은 191만 2,080명, 남성은 213만 183명입니다. 이처럼 세계 암의 이환율이 증가하고 있기 때문에 향후 몇 년간암 면역치료 수요가 높아질 전망입니다.

또한, 흡연, 방사선 노출, 특정 화학 물질에 대한 노출은 모두 암 위험 증가와 관련이 있습니다. 예를 들어, 엡스타인 바 바이러스, HIV, 인간 T 세포 림프종 및 백혈병 바이러스 감염은 림프종과 백혈병을 일으키는 위험 인자입니다. 따라서 위의 요인 중 하나에 노출되는 기회가 늘어나면 혈액암 환자 수가 늘어납니다. 마찬가지로 위의 요인은 모든 유형의 암 위험을 증가시켜 암 유병률을 증가시켜 향후 몇 년동안 암 면역치료 수요를 증가시킬 수 있습니다.

또한 세계보건기구(WHO)(2022)에 따르면 2020년 세계 인구의 22.3%가 담배를 사용했고, 남성에서는 전체의 36.7%, 여성에서는 7.8%가 담배를 사용했습니다. 따라서, 담배 소비 증가는 암의 유병률을 더욱 증가시키고, 최종적으로 소정의 예측 기간에 있어서의 암 면역치료 수요를 증가시킵니다.

게다가 암 면역치료의 필요성에 관한 계발 활동 증가도 예측 기간에 시장 성장 촉진요인이 될 것으로 전망됩니다.

따라서 위의 요인이 종합적으로 2024년부터 2030년까지 예측기간에 암 면역치료 시장 전체를 견인합니다.

그러나 높은 치료비 및 면역치료의 부작용 등이 암 면역치료 시장의 성장에 있어서의 과제가 될 가능성이 있습니다.

COVID-19 팬데믹은 암 면역치료 시장에 약간의 영향을 미쳤습니다. 팬데믹의 발생은 암, 당뇨병, 심혈관 질환 등의 만성 질환에 대한 외래 진찰의 취소나 긴급성이 없는 병원이나 치료의 중지로 이어졌습니다. 그 결과 암 및 기타 위 질환의 정기적인 치료를 목적으로 하는 환자가 감소했습니다. 그러나 COVID-19의 백신 개발은 봉쇄 규제의 완화 및 경제 상황의 정상화라는 경제 회복 과정을 만들어 내고 외래 진찰과 같은 정상적인 의료 서비스 재개 과정을 시작하여 암 면역치료 시장에서의 제품 수요가 궤도에 올랐습니다.

암 면역치료 시장의 부문 분석

암 면역치료 시장의 유형 부문에서는 2023년에 단클론항체 부문이 큰 수익 점유율을 차지한 것으로 평가되었습니다. 이것은 주로 다른 유형에 비해 이 부문 우위의 고리가 넓기 때문이었습니다.

단클론항체는 재현성 및 확장성이 높고 생산 원료에 제한이 없기 때문에 세계에서 가장 일반적으로 처방되는 면역치료제입니다. 또한, 단클론항체는 분석의 감도와 특이성을 제공합니다.

또한, 단클론항체는 암세포와 세포 증식을 촉진하는 단백질과의 결합을 저해합니다. 이것은 암의 증식과 생존에 필요한 활성이며 암세포에 대한 적절한 치료법입니다.

본 보고서에서는 세계의 암 면역치료 시장에 대해 조사 분석하여 시장 규모 및 예측, 촉진요인 및 과제, 기업 및 제품 프로파일 등의 정보를 제공합니다.

목차

제1장 암 면역치료 시장 보고서의 서문

제2장 암 면역치료 시장의 주요 요약

  • 조사 범위
  • 시장 개요
  • 경쟁 평가

제3장 규제 분석

  • 미국
  • 유럽
  • 일본
  • 중국

제4장 암 면역치료 시장의 주요 요인 분석

  • 암 면역치료 시장 성장 촉진요인
  • 암 면역치료 시장 성장 억제요인 및 과제
  • 암 면역치료 시장의 기회

제5장 암 면역치료 시장의 Porter's Five Forces 분석

제6장 암 면역치료 시장에 대한 COVID-19의 영향 분석

제7장 암 면역치료 시장 레이아웃

  • 유형별
    • 단클론항체
    • 면역조절제
    • 암 백신
    • 체크포인트 억제제
    • 기타
  • 적응증별
    • 폐암
    • 유방암
    • 전립선암
    • 대장암
  • 최종 사용자별
    • 병원 및 진료소
    • 전문센터
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 기타 지역

제8장 암 면역치료 시장 기업 및 제품 프로파일

  • Amgen Inc.
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd
  • Bayer AG
  • Bristol-Myers Squibb
  • Eli Lilly and Co
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • Gilead Sciences, Inc.
  • Dendreon Pharmaceuticals LLC.
  • Fate Therapeutics
  • Precision BioSciences
  • IOVANCE Biotherapeutics, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Sanofi
  • Mylan NV
  • Apotex Inc.
  • Hikma Pharmaceuticals PLC

제9장 KOL의 견해

제10장 프로젝트 접근법

제11장 DelveInsight 정보

제12장 면책사항 및 문의

AJY 24.04.09

CANCER IMMUNOTHERAPY MARKET BY TYPE (MONOCLONAL ANTIBODIES, IMMUNOMODULATORS, CANCER VACCINES, CHECKPOINT INHIBITORS, AND OTHERS), BY INDICATION (LUNG CANCER, BREAST CANCER, PROSTATE CANCER, COLORECTAL CANCER, AND OTHERS), BY END-USER (HOSPITALS AND CLINICS, SPECIALTY CENTERS, AND OTHERS), AND BY GEOGRAPHY IS EXPECTED TO RISE AT A SIGNIFICANT CAGR FORECAST till 2030 OWING TO THE ACCELERATING PREVALENCE OF CANCERS AND SURGING HEALTHCARE EXPENDITURE ACROSS THE GLOBE

The global cancer immunotherapy market is found to be 85.23 billion in 2022 and will grow at a CAGR of 11.63% during the forecast period from 2024 to 2030 in order to reach USD 162.87 billion by 2030. The cancer immunotherapy market is observing an optimistic market growth due to the factors such as the rising prevalence of cancer across the globe and the increasing exposure to carcinogenic substances, smoking, radiation, viruses, and others. Further, the surging healthcare expenditure and the growing adoption of cancer immunotherapy over other treatment options will also drive the market of cancer immunotherapy market in the given forecast period. Therefore, the market for cancer immunotherapy is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.

CANCER IMMUNOTHERAPY MARKET DYNAMICS:

One of the key aspect for driving the cancer immunotherapy market is the rising prevalence of cancers globally.

For instance, according to the World Health Organization (WHO) 2022, in 2020 the incidence of breast cancer was 2.26 million cases, followed by lung cancer -2.21 million cases, colon and rectum cancer with 1.93 million cases, prostate cancer with 1.41 million cases, skin cancer 1.20 million cases, and stomach cancer with 1.09 million cases, globally. Also, as per the database provided by the European Commission, the incidence of cancer among the women in Europe in 2020 was 1,912,080 and in males was 2,130,183. Thus, the increasing incidence of cancers across the globe will increase the demand of cancer immunotherapy in the upcoming years.

Further, smoking, radiation exposure, and exposure to certain chemicals have all been linked to the increased risk of cancers. For instance, Epstein-Barr virus, HIV and human T-cell lymphoma/leukemia virus infections are risk factors for developing lymphomas and leukemia. Thus, increased exposure to any of the above factor will increase the number of cases of blood cancer. In the same manner the above mentioned factors can increase the risk of any type of cancer, ultimately increasing the prevalence of cancer, thereby increasing the demand of cancer immunotherapy in the upcoming years.

Also, according to the World Health Organization (WHO) 2022, in 2020, 22.3% of the global population used tobacco, 36.7% of all men and 7.8% of the world's women. Thus, the increased consumption of tobacco will further increase the prevalence of cancers, ultimately increasing the demand of cancer immunotherapy in the given forecast period.

Additionally, increase in the awareness programs regarding the need for cancer immunotherapy is expected to help the market gain traction during the forecast period.

Therefore, the factors stated above collectively will drive the overall cancer immunotherapy market during the forecast period from 2024-2030.

However, high cost of the treatment, adverse effects of immunotherapy treatment, and others may prove to be challenging factors for cancer immunotherapy market growth.

The COVID-19 pandemic has slightly impacted the market for cancer immunotherapy. The outbreak of the pandemic led to the cancellation of outpatient visits and the suspension of non-emergency hospitals and procedures for chronic disorders such as cancers, diabetes, cardiovascular disorders, others. This resulted in the reduced number of patients for the routine treatments of the cancer and other above mentioned disorders. However, vaccine development of COVID-19 has produced the process of economic recovery with the easing of lockdown restrictions and the return of normalcy in the economic landscape which has initiated the process of resumption of regular healthcare services such as outpatient's visits, thereby bringing the demand for products on track in the cancer immunotherapy market.

CANCER IMMUNOTHERAPY MARKET SEGMENT ANALYSIS:

Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Immunomodulators, Cancer Vaccines, Checkpoint Inhibitors, and Others), Indication (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, and Others), End-User (Hospitals and Clinics, Specialty Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the type segment of the cancer immunotherapy market, the monoclonal antibodies segment is expected to have a significant revenue share in the year 2023. This was primarily owing to the wider advantage circle of the segment as compared to the other type.

Monoclonal antibodies are the most commonly prescribed immunotherapeutic drugs across the globe as they are highly reproducible and scalable, and have unlimited production source. Moreover, the monoclonal antibodies offers sensitivity and specificity of assays.

Also, they block the connection between a cancer cell and proteins that promote cell growth, an activity that is necessary for cancer growth and survival, thereby making it an apt treatment for the cancer cells.

Further, the monoclonal antibodies are a type of targeted cancer therapy, which means they are designed to interact with specific targets. This property decreases the number of adverse events related with the therapy.

Also, the increasing investments in research & development of monoclonal antibodies as naked antigen binding antibodies, conjugated monoclonal antibodies, and bispecific antibodies have opened up new revenue streams for oncology therapeutics companies. These R&D efforts have resulted in the introduction of mAbs with properties such as adaptive immunity, antigen specificity, and antibody dependent cellular toxicity. Owing of their numerous advantages, mAbs are being used and researched for the treatment of various types of tumors.

Therefore, owing to the advantages and applications associated with the monoclonal antibodies, the category is expected to witness a considerable growth eventually contributing to the overall growth of the global cancer immunotherapy market during the forecast period.

NORTH AMERICA IS EXPECTED TO DOMINATE THE OVERALL CANCER IMMUNOTHERAPY MARKET:

Among all the regions, the North America is expected to dominate the global cancer immunotherapy in the year 2023 and is expected to do the same during the forecast period from 2024-2030. This can be ascribed to the increasing prevalence of cancers, the increasing exposure to carcinogenic substances, smoking, radiation, viruses, and the presence of key market players in the region are factors which acts as a supportive factor for the North America cancer immunotherapy market growth.

According to the American Cancer Society 2022, in 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States. Also, according to the Canadian Centre for Applied Research in Cancer Control 2022, nearly 233,900 estimated cases will be reported in 2022, in Canada. Further, the global cancer observatory 2022, stated that the incidence of cancer in 2020 in Mexico was 195,499. Thus, from the above mentioned sources and statistics it can be concluded that the incidence of cancer is quite high in the North America, ultimately increasing the demand of cancer immunotherapy in the region.

Further, the increasing geriatric population in the region, increasing consumption of tobacco, alcohol, chemicals, and other carcinogenic substances, will surge the market of cancer immunotherapy market. For instance, according to the United Health Foundation 2022, more than 54 million adults ages 65 and older live in the United States, in 2022. Further, as per the U.S. Census Bureau 2022, the geriatric population accounts for about 16.5% of the nation's population. The source also stated that the number of older adults living in the United States is large and growing and is estimated that by 2050, the total number of adults ages 65 and older is projected to rise to an estimated 85.7 million which is roughly 20% of the overall United States population. Thus, the increasing elderly population will increase the demand of cancer immunotherapy as the elderly patients have weak immune systems and are more prone cancers and other chronic disease.

Further, increasing ease of access to modern therapeutics, presence of key players, increasing healthcare expenditure, and others will also spur the market of cancer immunotherapy in the upcoming years.

Therefore, the interplay of the aforementioned factors above would provide a conducive growth environment for the North American region in the cancer immunotherapy market.

CANCER IMMUNOTHERAPY MARKET KEY PLAYERS:

Some of the key market players operating in the cancer immunotherapy market includes Amgen Inc., AstraZeneca, F. Hoffmann-La Roche Ltd, Bayer AG, Bristol-Myers Squibb, Eli Lilly and Co., Merck & Co., Inc., Novartis AG, Pfizer Inc., Johnson & Johnson Services, Inc., Gilead Sciences, Inc., Dendreon Pharmaceuticals LLC., Fate Therapeutics, Precision BioSciences, IOVANCE Biotherapeutics, Inc., Spectrum Pharmaceuticals, Inc., Sanofi, Mylan N.V., Apotex Inc., Hikma Pharmaceuticals PLC, and others.

RECENT DEVELOPMENTAL ACTIVITIES IN CANCER IMMUNOTHERAPY MARKET:

In February 2022, The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration approved CARVYKTI, a cancer immunotherapy for the treatment of adults with relapsed or refractory multiple myeloma (RRMM).

In April 2022, the U.S. Food and Drug Administration approved Opdivo (nivolumab), in combination with certain types of chemotherapy, for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer as well as esophageal adenocarcinoma. This is the first FDA-approved immunotherapy for the first-line treatment of gastric cancer.

KEY TAKEAWAYS FROM THE CANCER IMMUNOTHERAPY MARKET REPORT STUDY

  • Market size analysis for current cancer immunotherapy market size (2023), and market forecast for 5 years (2024-2030)
  • The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the cancer Immunotherapy market.
  • Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
  • Key companies dominating the global cancer immunotherapy market.
  • Various opportunities available for the other competitor in the cancer immunotherapy market space.
  • What are the top performing segments in 2023? How these segments will perform in 2030.
  • Which is the top-performing regions and countries in the current cancer immunotherapy market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for cancer immunotherapy market growth in the coming future?

TARGET AUDIENCE WHO CAN BE BENEFITED FROM THIS CANCER IMMUNOTHERAPY MARKET REPORT STUDY

  • Cancer immunotherapy products providers
  • Research organizations and consulting companies
  • Cancer immunotherapy -related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in cancer immunotherapy
  • Various end users who want to know more about the cancer immunotherapy market and latest technological developments in the cancer immunotherapy market.

FREQUENTLY ASKED QUESTIONS FOR CANCER IMMUNOTHERAPY MARKET:

1. What is a cancer immunotherapy?

The cancer immunotherapy, also known as immuno-oncology, is a form of cancer treatment that uses the power of the body's own immune system to prevent, control, and eliminate cancer.

2. What is the global market for cancer immunotherapy?

The global cancer immunotherapy market is found to be 85.23 billion in 2022 and will grow at a CAGR of 11.63% during the forecast period from 2024 to 2030 in order to reach USD 162.87 billion by 2030.

3. What are the drivers for global cancer immunotherapy market?

The cancer immunotherapy market is witnessing a positive market growth owing to the factors such as the rising prevalence of cancer across the globe and the increasing exposure to carcinogenic substances, smoking, radiation, viruses, and others will increase the demand of cancer immunotherapy in the market. Further, the surging healthcare expenditure and the growing adoption of cancer immunotherapy over other treatment options will also drive the market of cancer immunotherapy market in the given forecast period.

4. Who are the key players operating in the global cancer immunotherapy market?

Some of the key market players operating in the cancer immunotherapy market includes Amgen Inc., AstraZeneca, F. Hoffmann-La Roche Ltd, Bayer AG, Bristol-Myers Squibb, Eli Lilly and Co., Merck & Co., Inc., Novartis AG, Pfizer Inc., Johnson & Johnson Services, Inc., Gilead Sciences, Inc., Dendreon Pharmaceuticals LLC., Fate Therapeutics, Precision BioSciences, IOVANCE Biotherapeutics, Inc., Spectrum Pharmaceuticals, Inc., Sanofi, Mylan N.V., Apotex Inc., Hikma Pharmaceuticals PLC, and others.

5. Which region has the highest share in cancer immunotherapy market?

Among all the regions, North America is estimated to hold the significant revenue share in the global cancer immunotherapy market. This can be ascribed to the increasing prevalence of cancers in the region, the increasing exposure to carcinogenic substances, smoking, radiation, viruses, and the presence of key market players in the region are factors which acts as a supportive factor for the North America cancer immunotherapy market growth.

Table of Contents

1. Cancer Immunotherapy Market Report Introduction

2. Cancer Immunotherapy Market Executive Summary

  • 2.1 Scope of the Study
  • 2.2 Market at Glance
  • 2.3 Competitive Assessment

3. Regulatory Analysis

  • 3.1 The United States
  • 3.2 Europe
  • 3.3 Japan
  • 3.4 China

4. Cancer Immunotherapy Market Key Factors Analysis

  • 4.1 Cancer Immunotherapy Market Drivers
    • 4.1.1 The rising prevalence of cancer across the globe
    • 4.1.2 Increasing exposure to carcinogenic substances, smoking, radiation, viruses, and others
    • 4.1.3 Growing Adoption of Cancer Immunotherapy over Other Treatment Options
    • 4.1.4 Surge in healthcare expenditure
  • 4.2 Cancer Immunotherapy Market Restraints and Challenges
    • 4.2.1 High Cost of Treatment
    • 4.2.2 Adverse Effects of Immunotherapy Treatment
  • 4.3 Cancer Immunotherapy Market Opportunities
    • 4.3.1 Development of Bioinformatics Tools and Targeted Therapy
    • 4.3.2 Growing awareness regarding proper treatment and management of cancers

5. Cancer Immunotherapy Market Porter's Five Forces Analysis

  • 5.1 Bargaining Power of Suppliers
  • 5.2 Bargaining Power of Consumers
  • 5.3 Threat of New Entrants
  • 5.4 Threat of Substitutes
  • 5.5 Competitive Rivalry

6. COVID-19 Impact Analysis on Cancer Immunotherapy Market

7. Cancer Immunotherapy Market Layout

  • 7.1 By Type
    • 7.1.1 Monoclonal Antibodies
    • 7.1.2 Immunomodulators
    • 7.1.3 Cancer Vaccines
    • 7.1.4 Checkpoint Inhibitors
    • 7.1.5 Others
  • 7.2 By Indication
    • 7.2.1 Lung Cancer
    • 7.2.2 Breast Cancer
    • 7.2.3 Prostate Cancer
    • 7.2.4 Colorectal Cancer
    • 7.2.5 Others
  • 7.3 By End-User
    • 7.3.1 Hospitals and Clinics
    • 7.3.2 Specialty Centers
    • 7.3.3 Others
  • 7.4 By Geography
    • 7.4.1 North America
      • 7.4.1.1 United States Cancer Immunotherapy Market in USD million (2021-2030)
      • 7.4.1.2 Canada Cancer Immunotherapy Market in USD million (2021-2030)
      • 7.4.1.3 Mexico Cancer Immunotherapy Market in USD million (2021-2030)
    • 7.4.2 Europe
      • 7.4.2.1 France Cancer Immunotherapy Market in USD million (2021-2030)
      • 7.4.2.2 Germany Cancer Immunotherapy Market in USD million (2021-2030)
      • 7.4.2.3 United Kingdom Cancer Immunotherapy Market in USD million (2021-2030)
      • 7.4.2.4 Italy Cancer Immunotherapy Market in USD million (2021-2030)
      • 7.5.2.5 Spain Cancer Immunotherapy Market in USD million (2021-2030)
      • 7.4.2.6 Russia Cancer Immunotherapy Market in USD million (2021-2030)
      • 7.4.2.7 Rest of Europe Cancer Immunotherapy Market in USD million (2021-2030)
    • 7.4.3 Asia-Pacific
      • 7.4.3.1 China Cancer Immunotherapy Market in USD million (2021-2030)
      • 7.4.3.2 Japan Cancer Immunotherapy Market in USD million (2021-2030)
      • 7.4.3.3 India Cancer Immunotherapy Market in USD million (2021-2030)
      • 7.4.3.4 Australia Cancer Immunotherapy Market in USD million (2021-2030)
      • 7.4.3.5 South Korea Cancer Immunotherapy Market in USD million (2021-2030)
      • 7.4.3.6 Rest of Asia Pacific Cancer Immunotherapy Market in USD million (2021-2030)
    • 7.4.4 Rest of the World (RoW)
      • 7.4.4.1. Middle East Cancer Immunotherapy Market in USD million (2021-2030)
      • 7.4.4.2 Africa Cancer Immunotherapy Market in USD million (2021-2030)
      • 7.4.4.3 South America Cancer Immunotherapy Market in USD million (2021-2030)

8. Cancer Immunotherapy Market Company and Product Profiles

  • 8.1 Amgen Inc.
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4 Product Listing
    • 8.1.5. Entropy
  • 8.2 AstraZeneca
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4 Product Listing
    • 8.2.5. Entropy
  • 8.3 F. Hoffmann-La Roche Ltd
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4 Product Listing
    • 8.3.5. Entropy
  • 8.4 Bayer AG
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4 Product Listing
    • 8.4.5. Entropy
  • 8.5 Bristol-Myers Squibb
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4 Product Listing
    • 8.5.5. Entropy
  • 8.6 Eli Lilly and Co
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4 Product Listing
    • 8.6.5. Entropy
  • 8.7 Merck & Co., Inc.
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4 Product Listing
    • 8.7.5. Entropy
  • 8.8 Novartis AG
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4 Product Listing
    • 8.8.5. Entropy
  • 8.9 Pfizer Inc.
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4 Product Listing
    • 8.9.5. Entropy
  • 8.10 Johnson & Johnson Services, Inc.
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4 Product Listing
    • 8.10.5. Entropy
  • 8.11 Gilead Sciences, Inc.
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4 Product Listing
    • 8.11.5. Entropy
  • 8.12 Dendreon Pharmaceuticals LLC.
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4 Product Listing
    • 8.12.5. Entropy
  • 8.13 Fate Therapeutics
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4 Product Listing
    • 8.13.5. Entropy
  • 8.14 Precision BioSciences
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4 Product Listing
    • 8.14.5. Entropy
  • 8.15 IOVANCE Biotherapeutics, Inc.
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4 Product Listing
    • 8.15.5. Entropy
  • 8.16 Spectrum Pharmaceuticals, Inc.
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4 Product Listing
    • 8.16.5. Entropy
  • 8.17 Sanofi
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4 Product Listing
    • 8.17.5. Entropy
  • 8.18 Mylan N.V.
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4 Product Listing
    • 8.18.5. Entropy
  • 8.19 Apotex Inc.
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4 Product Listing
    • 8.19.5. Entropy
  • 8.20 Hikma Pharmaceuticals PLC
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4 Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제